School Progress Survey—Respondents: 2,025; Average Burden per Response: 30 minutes; Total Burden for Child School Progress Survey: 1012 hours—Total Burden: 4,477 hours.

OMB Desk Officer: Allison Eydt

Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 690–6207. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street N.W., Washington, D.C. 20503.

Comments may also be sent to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue S.W., Washington DC, 20201. Written comments should be received within 30 days of this notice.

Dated: May 29, 1996.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 96–14398 Filed 6–6–96; 8:45 am]

BILLING CODE 4150–04–M

Public Health Service

National Institutes of Health

Submission for OMB Review; Comment Request; National 5 A Day for Better Health Follow-Up Survey

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request to review and approve the information on collection listed below. This proposed information collection was previously published in the Federal Register on March 12, 1996, page 10001 and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: *Title:* The National 5 A Day for Better Health Follow-up Study. *Type of Information Collection Request:* NEW. *Need and Use of Information Collection:* This study will measure five year trends in fruit and vegetable intakes and in knowledge, attitudes, and beliefs about diet and nutrition specific to fruit and vegetable intake. The primary objectives of the study are to establish current patterns in fruit and vegetable consumption, beliefs and fruit and vegetables and health, program visibility and awareness, and changes in these since baseline. The findings will provide valuable information concerning (1) the effectiveness of the National 5 A Day for Better Health Program in the first five years of its existence, and (2) will be used for program planning to help direct further 5 A Day and other intervention efforts. *Frequency of Response:* One time. *Affected Public:* Individuals or Households. *Type of Respondents:* U.S. adults 18 years and older residing in these coterminous states. The annual reporting burden is as follows:

Type of respondents	Estimated number of respondents	Estimated number of responses per respondent	Average burden hours per response	Estimated total annual burden hours requested
Group 1	2000	1	.501	1002
Group 2	2050	1	.501	514
Non-Response	150	1	.167	25
Total	4200	1	.3669	1541

The annualized cost to respondents is estimated at: $12,410. There are no Capital Costs to report. There are no Operating to Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden to the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

DIRECT COMMENTS TO OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH.

To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Amy F. Subar, Ph.D., Susan M. Krebs-Smith, Ph.D., National Cancer Institute, EPN 313, 6130 Executive Blvd, Bethesda, MD 20892–7344, or call non-toll-free number (301) 496–8500.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: May 30, 1996.

Phillip D. Amoruso,

Executive Officer, NCI.

[FR Doc. 96–14430 Filed 6–6–96; 8:45 am]

BILLING CODE 4140–01–M

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Eric T. Fossel, Ph.D., Harvard Medical School: Based on ORI's analysis of the relevant evidence and conclusions submitted by the Harvard Medical

School Committee on Faculty Conduct, ORI found that Eric T. Fossel, Ph.D., former Harvard Medical School Associate Professor of Radiology at Beth Israel Hospital, committed scientific misconduct by reporting falsified research results in a Public Health Service (PHS) grant application.

Specifically, Dr. Fossel altered nuclear magnetic resonance (NMR) data in the Multicenter Breast Trial (MCBT) such that the NMR test, purporting to detect from a patient's blood sample a predisposition toward malignancy or a relapse, appeared to be more accurate, sensitive, and specific than was actually the case. Premised on these falsely reported results, Dr. Fossel proposed in a PHS grant application that the National Cancer Institute provide funds to complete the MCBT.

Dr. Fossel has entered into a Voluntary Exclusion Agreement with ORI in which he has voluntarily agreed, for the three (3) year period beginning May 9, 1996, to exclude himself from:

(1) any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations), and

(2) serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

No scientific publications were required to be corrected as part of this Agreement.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 96–14389 Filed 6–6–96; 8:45 am]

BILLING CODE 4160–17–P

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Teleconference Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 1, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.-5 p.m., June 24, 1996.

Place: National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, ''Cooperative Agreements for Prevention Centers/ NCCDPHP—General Special Interest Projects.''

Contact Person for More Information: James E. Barrow, Deputy Director, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/ 488–5269.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers Program/ NCCDPHP—General Special Interest Projects, Panel Number 2, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.–5 p.m., June 25, 1996.

Place: NCCDPHP, CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, ''Cooperative Agreements for Prevention Centers/ NCCDPHP—General Special Interest Projects.''

Contact Person for More Information: Michael N. Waller, Program Manager, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488–5292.

Name: Disease, Disability, and Injury Prevention and Control SEP: Cooperative Agreements for Prevention Centers Program/ NCCDPHP—General Special Interest Projects, Panel Number 3, Program Announcements 328, 432, and 461.

Time and Date: 1 p.m.–5 p.m., June 26, 1996.

Place: NCCDPHP, CDC, Rhodes Building, Koger Office Park, 3005 Chamblee-Tucker Road, Atlanta, Georgia 30341.

Status: Closed.

Matters To Be Considered: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461 entitled, ''Cooperative Agreements for Prevention Centers/ NCCDPHP—General Special Interest Projects.''

Contact Person for More Information: Craig L. Leutzinger, Public Health Advisor, Division of Adult and Community Health, NCCDPHP, CDC, 4770 Buford Highway, NE, M/S K30, Chamblee, Georgia 30341, telephone 770/488–5304.

These meetings will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Dated: May 31, 1996.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–14381 Filed 6–6–96; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

Advisory Committee Meeting; Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is cancelling the meeting of the Science Board to the Food and Drug Administration scheduled for June 13, 1996, to provide time for the agency to continue its development of strategies to address toxicity, carcinogenicity, and biomaterials testing. The meeting was announced in the Federal Register of May 24, 1996 (61 FR 26187).

FOR FURTHER INFORMATION CONTACT: Susan A. Homire, Office of Science (HF–33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3340; or call the FDA Advisory Committee Information Hotline, 1–800–741–8138 (301–443–0572) in the Washington, DC area, Science Board to the Food and Drug Administration, code 12603.

Dated: June 3, 1996.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 96–14388 Filed 6–06–96; 8:45 am]

BILLING CODE 4160–01–F

Memorandum of Understanding Between the Food and Drug Administration and the U.S. Department of Agriculture and the Russian Federation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the U.S. Department of Agriculture and